Epidermal growth factor receptor blockers for the treatment of ovarian cancer (Q24240523)

2

0 references

Shibani Nicum

3

0 references

Sean Kehoe

4

0 references

Jo Morrison

Cochrane Database of Systematic Reviews

5

0 references

language of work or name

1 reference

8 July 2009

0 references

published in

0 references

cites work

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Mechanism of action of trastuzumab and scientific update

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007927

7 January 2021